Insider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $217,891.37 in Stock

Sera Prognostics, Inc. (NASDAQ:SERAGet Free Report) CEO Zhenya Lindgardt sold 26,867 shares of the business’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $8.11, for a total transaction of $217,891.37. Following the completion of the transaction, the chief executive officer now directly owns 869,245 shares in the company, valued at $7,049,576.95. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Zhenya Lindgardt also recently made the following trade(s):

  • On Wednesday, May 8th, Zhenya Lindgardt sold 11,992 shares of Sera Prognostics stock. The stock was sold at an average price of $9.59, for a total transaction of $115,003.28.
  • On Tuesday, March 26th, Zhenya Lindgardt sold 38,899 shares of Sera Prognostics stock. The stock was sold at an average price of $9.37, for a total transaction of $364,483.63.

Sera Prognostics Stock Performance

Shares of Sera Prognostics stock opened at $8.04 on Friday. Sera Prognostics, Inc. has a 52-week low of $1.52 and a 52-week high of $12.35. The stock’s 50-day simple moving average is $9.37 and its 200 day simple moving average is $7.90.

Sera Prognostics (NASDAQ:SERAGet Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 46.35%. On average, sell-side analysts predict that Sera Prognostics, Inc. will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Sera Prognostics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. bought a new stake in Sera Prognostics in the 1st quarter valued at about $18,420,000. AWM Investment Company Inc. increased its position in shares of Sera Prognostics by 56.0% during the first quarter. AWM Investment Company Inc. now owns 584,664 shares of the company’s stock valued at $5,320,000 after buying an additional 209,762 shares during the period. Sanders Morris Harris LLC bought a new stake in shares of Sera Prognostics during the first quarter valued at about $174,000. StepStone Group LP bought a new stake in shares of Sera Prognostics during the fourth quarter valued at about $61,000. Finally, CWM LLC bought a new stake in shares of Sera Prognostics during the fourth quarter valued at about $242,000. 54.64% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, William Blair reissued an “outperform” rating on shares of Sera Prognostics in a report on Friday, May 10th.

View Our Latest Research Report on Sera Prognostics

About Sera Prognostics

(Get Free Report)

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

See Also

Insider Buying and Selling by Quarter for Sera Prognostics (NASDAQ:SERA)

Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.